House Secondary Banner
 

Research Grants Overview


 

 

Research Grants Overview


Rockland Immunochemicals Inc. actively participates in the Small Business Innovation Research (SBIR) program which is a highly competitive program that encourages domestic small businesses to engage in Federal Research/Research and Development that has the potential for commercialization. Rockland has achieved significant breakthroughs through the competitive SBIR award process to develop technologies that are ultimately made available to the research community.

  SBIR/STTR

 


 


Success through Collaboration


Rockland successfully leverages the technical expertise of its staff by collaborating with principal investigators at academic and research facilities throughout North America, Europe and Japan including, but not limited to, Scripps Institute, Memorial Sloan-Kettering Cancer Center, Fox Chase Cancer Center, the Wistar Institute, UNC Lineberger Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, St. Jude's Children's Research Hospital, and Children’s Hospital of Philadelphia. Several R&D projects at Rockland Immunochemicals are in collaboration with agencies of the National Institutes of Health (NIH). With the National Cancer Institute we have developed novel antibody reagents and antibody-based assays for newly identified protein targets critical for the cancer research.

  SuccessthroughCollaboration




Recent Phase I and Phase II SBIR Grants and Awards


 

Rockland is successful in the competitive peer-reviewed process to receive SBIR grants and awards from the NIH. Funding allows Rockland Immunochemicals to develop innovative and cutting-edged research tools for the biomedical research community. These prestigious awards reaffirm our innovation and commitment to research and biotechnology. Below is a partial list of recent grants and awards successfully funded through the SBIR process. Click on the grant title for more information.


 


NCI   NationalInstituteofAllergyandInfectiousDisease   NIEHS


Grant and Contract Title Year Award Status Agency
1R43HL123472-01 Antibody-based point-of-care device for the diagnosis of sickle cell disease 2014 Phase I Active NHLBI
1R43DA038982-01 Synthetic antibodies for monitoring modified RNAs 2014  Phase I Active NIDA
HHSN261201300059C Novel imaging agents to expand the clinical toolkit 2013 Phase I Active NCI  
HHSN261201100087C Pharmacodynamic assay for AKT/mTOR inhibitors 2011 Phase II Active NCI  
HHSN26100900070C   Pharmacodynamic assay for AKT/mTOR inhibitors 2009 Phase I Completed NCI  
HHSN261201100104C Pharmacodynamic assay for c-Met family members 2011 Phase I Completed NCI  
HHSN261201000105C Multiplexed assays for AKT/mTOR pathway 2010 Phase I Completed NCI  
HHSN261201000093C Generic Antibodies for the Treatment of Cancer 2010 Phase I Completed NCI  
1R43AI084296-01   Novel point-of-care multiplex Lyme disease test 2009 Phase I Completed NIAID  
HHSN273200700018C Reagents and a kit for measuring NAG-1 serum levels 2008 Phase II Completed NIEHS  
HHSN273200700018C Reagents and a kit for measuring NAG-1 serum levels 2006 Phase I Completed NIEHS  

 

 

Rockland Immunochemicals welcomes joint venture opportunities in partnering with researchers from both for-profit and non-profit institutions to expand funding opportunities in the Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) programs. Academic researchers and small businesses interested in exploring joint opportunities are encouraged to contact grants@rockland-inc.com.
 

Reference Rockland Bucket

 

 

 

New Lab Set Up